Inloggad som:
Magnetismm-5
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Magnetismm-5
En fas 3-studie av elranatamab (PF-06863135) som monoterapi och elranatamab + daratumumab jämfört med daratumumab + pomalidomid + dexametason hos deltagare med recidiverande/refraktärt multipelt myelom
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Skånes universitetssjukhus / Hematologisk vård
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Mer information om studien för vårdgivare
Participants age ≥18 years (or the minimum country-specific age of consent if >18).
Prior diagnosis of multiple myeloma (MM) as defined according to IMWG criteria.
See link for more info
Smoldering MM.
Plasma cell leukemia.
Amyloidosis, Waldenström’s macroglobulinemia, or polyneuropathy, organomegaly,
endocrinopathy, myeloma protein, and skin changes (POEMS) Syndrome.
Behandling
Fas 3
Kurativ
Ej tillämpbar
Företag
Studien ändrades senast: (2025-09-30)